BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6306835)

  • 1. Methotrexate and 5-fluorouracil following tamoxifen and premarin in advanced breast cancer.
    Allegra JC
    Semin Oncol; 1983 Jun; 10(2 Suppl 2):23-8. PubMed ID: 6306835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer.
    Allegra JC; Woodcock TM; Richman SP; Bland KI; Wittliff JL
    Breast Cancer Res Treat; 1982; 2(1):93-9. PubMed ID: 6293630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized attempt to increase the efficacy of cytotoxic chemotherapy in metastatic breast cancer by hormonal synchronization.
    Lippman ME; Cassidy J; Wesley M; Young RC
    J Clin Oncol; 1984 Jan; 2(1):28-36. PubMed ID: 6321686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increasing the response rate to cytotoxic chemotherapy by endocrine means.
    Lippman ME; Cassidy J; Wesley M; Young RC
    J Steroid Biochem; 1985 Dec; 23(6B):1173-80. PubMed ID: 3005774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of locally advanced breast cancer using primary induction chemotherapy with hormonal synchronization followed by radiation therapy with or without debulking surgery.
    Lippman ME; Sorace RA; Bagley CS; Danforth DW; Lichter A; Wesley MN
    NCI Monogr; 1986; (1):153-9. PubMed ID: 3022156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytoxan, epirubicin, methotrexate and 5-fluorouracil with hormonal synchronization (tamoxifen/premarin) in advanced breast cancer. Preliminary results.
    Zaniboni A; Simoncini E; Marpicati P; Gorni F; Cervi GC; Marini G
    Chemioterapia; 1986 Oct; 5(5):341-6. PubMed ID: 3024851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen and conjugated estrogens (Premarin) followed by sequenced methotrexate and 5-FU in refractory advanced breast cancer.
    Eisenhauer EA; Bowman DM; Pritchard KI; Paterson AH; Ragaz J; Plenderleith I; Geggie PH; Maxwell I
    Cancer Treat Rep; 1984 Nov; 68(11):1421-2. PubMed ID: 6094005
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.
    Rivkin SE; Green S; Metch B; Cruz AB; Abeloff MD; Jewell WR; Costanzi JJ; Farrar WB; Minton JP; Osborne CK
    J Clin Oncol; 1994 Oct; 12(10):2078-85. PubMed ID: 7931477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction chemotherapy of dibromodulcitol, Adriamycin, vincristine, tamoxifen, and Halotestin with methotrexate in metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1181).
    Chang AY; Putt M; Pandya KJ; Harris J; Gelman R; Tormey DC; Falkson G
    Am J Clin Oncol; 1998 Feb; 21(1):99-104. PubMed ID: 9499270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. Breast Cancer Site Group.
    Pritchard KI; Paterson AH; Fine S; Paul NA; Zee B; Shepherd LE; Abu-Zahra H; Ragaz J; Knowling M; Levine MN; Verma S; Perrault D; Walde PL; Bramwell VH; Poljicak M; Boyd N; Warr D; Norris BD; Bowman D; Armitage GR; Weizel H; Buckman RA
    J Clin Oncol; 1997 Jun; 15(6):2302-11. PubMed ID: 9196144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined cytotoxic and endocrine treatment of postmenopausal patients with advanced breast cancer: preliminary results of a phase II study of the combination of prednimustine, novantrone, methotrexate, 5-fluorouracil, and tamoxifen.
    Mouridsen HT; Andersson M; Pedersen L
    Semin Oncol; 1986 Mar; 13(1 Suppl 1):39-41. PubMed ID: 3952520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical modulation of fluorouracil: comparison of methotrexate, folinic acid, and fluorouracil versus folinic acid and fluorouracil in advanced colorectal cancer: a randomized trial.
    Polyzos A; Tsavaris N; Giannopoulos A; Bacoyiannis C; Papadimas V; Kalahanis N; Karatzas G; Kosmas C; Sakelaropoulos N; Archimandritis A; Papachristodoulou A; Kosmidis P
    Cancer Chemother Pharmacol; 1996; 38(3):292-7. PubMed ID: 8646806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential administration of cyclophosphamide, methotrexate, 5-fluorouracil, and folinic acid as salvage treatment in metastatic breast cancer.
    Pronzato P; Amoroso D; Ardizzoni A; Bertelli G; Canobbio L; Conte PF; Cusimano MP; Fusco V; Gulisano M; Lionetto R
    Am J Clin Oncol; 1987 Oct; 10(5):404-6. PubMed ID: 3310605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment with mitoxantrone, methotrexate, vincristine, and carboplatine (MIMOC) plus cyclical hormonotherapy with tamoxifen and megestrol acetate in advanced breast cancer.
    Kakolyris S; Samonis G; Koukourakis M; Vlachonicolis J; Kalbakis K; Agelaki S; Chalkiadakis G; Sanidas E; Tsiftsis D; Georgoulias V
    Am J Clin Oncol; 1999 Jun; 22(3):273-7. PubMed ID: 10362335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prednimustine in combination with methotrexate and 5-FU (PMF): a pilot study.
    Boesen E; Mouridsen HT
    Cancer Treat Rep; 1982 Dec; 66(12):2081-3. PubMed ID: 7139649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced colorectal carcinoma. A prospective randomized trial of sequential methotrexate, 5-fluorouracil, and leucovorin versus 5-fluorouracil alone.
    Machiavelli M; Leone BA; Romero A; Rabinovich MG; Vallejo CT; Bianco A; Pérez JE; Rodríguez R; Cuevas MA; Alvarez LA
    Am J Clin Oncol; 1991 Jun; 14(3):211-7. PubMed ID: 2031508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sequential methotrexate-5-fluorouracil (MTX-5-FU) treatment of patients with advanced gastric and colorectal cancer. Sequential Methotrexate-5-FU Study Group].
    Murakami M; Ota K; Miyazaki T; Niitsu Y; Wakui A; Yokoyama M; Kanamaru R; Futatsuki K; Akazawa S; Sakai Y
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2482-90. PubMed ID: 3619460
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: a randomized trial of the Northern California Oncology Group.
    Valone FH; Friedman MA; Wittlinger PS; Drakes T; Eisenberg PD; Malec M; Hannigan JF; Brown BW
    J Clin Oncol; 1989 Oct; 7(10):1427-36. PubMed ID: 2789272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoendocrine therapy with prolonged estrogen priming in advanced breast cancer: endocrine pharmacokinetics and toxicity.
    Benz C; Gandara D; Miller B; Drakes T; Monroe S; Wilbur B; DeGregorio M
    Cancer Treat Rep; 1987 Mar; 71(3):283-9. PubMed ID: 3493069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.